Dödligt virus från Kina orsakar panik (SARS-CoV-2, COVID-19)

Cindy, who thought masks were only good memes, is currently hospitalized for nearly 100 days with some *brutal* treatments. Most likely brain dead.
Nominated

Carolyn wasn't going to let the media control her mind. Earns her HCA instead.
Awarded

Antivaxx Mike believed Trump won, Covid was a scamdemic, became a Freedom Tuber, and left his son a huge mess to sort through. Don’t be like Mike.
Awarded

Awarded posthumously. 🏆 #HermanCainAward nominations and removal requests (family of the deceased only) accepted via DM. We do not condone harassment.

Spreads misinformation about vaccines. Announces the sale of fake vaccination cards. Pushes Ivermectin. Catches COVID-19 and dies. We honor Lenny Mendez with a #HermanCainAward, with distinction, for working in healthcare and acting a fool during a pandemic.

Not a fan of mask mandates. Refuses to get vaccinated. Wants to "end Faucism." Catches COVID-19. Lasts 24 hours. We honor (former) Florida @GOP official Gregg Prentice with a #HermanCainAward.

Refuses to get vaccinated. Spreads conspiracy theories about vaccines. She and her husband catch COVID-19. GoFundMe created. Both die. We honor Walt and Susy Kussy with two #HermanCainAward(s).

Under de senaste veckorna har man sett en tydlig ökning i smittspridningen av covid-19 bland studenter.

– Det är en relativt väntad utveckling som vi ser, i och med terminsstarten, säger Uppsala universitets säkerhetschef Fredrik Blomqvist.

I nuläget kan man inte peka på ifall det är studentfester eller platsundervisning som är orsaken till smittan.

Trots att smittan ökat så har inte universitetet några planer på att återgå till distansundervisning. Det finns bara en faktor som skulle ändra det.

– Det finns ett beslut som skulle ändra det och det är om regeringen skulle fatta ett beslut om distansundervisning, säger Fredrik Blomqvist.

To the Editor — The global demand for prophylactic and treatment options for COVID-19 has in turn created a demand for both randomized clinical trials, and the synthesis of those trials into meta-analyses by systematic review. This process has been fraught, and has demonstrated the inherent risks in current approaches and accepted standards of quantitative evidence synthesis when dealing with high volumes of recent, often unpublished trial data of variable quality.

Research into the use of ivermectin (a drug that has an established safety and efficacy record in many parasitic diseases) for the treatment and/or prophylaxis of COVID-19 has illustrated this problem well. Recently, we described flaws in one randomized control trial of ivermectin1, the results of which represented more than 10% of the overall effect in at least two major meta-analyses2,3. We described several irregularities in the data that could not be consistent with them being experimentally derived4. That study has now been withdrawn by the preprint server5 on which it was hosted. We also raised concerns about unexpected stratification across baseline variables in another randomized controlled trial for ivermectin6, which were highly suggestive of randomization failure. We have requested data from the authors but, as of 6 September 2021, have not yet received a response. This second ivermectin study has now been published6, and there is still no response from the authors in a request for data.
/.../
We recognize that this is a change to long-accepted practice and is substantially more rigorous than the standards that are typically currently applied, but we believe that what has happened in the case of ivermectin justifies our proposal: a poorly scrutinized evidence base supported the administration of millions of doses of a potentially ineffective drug globally, and yet when this evidence was subjected to a very basic numerical scrutiny it collapsed in a matter of weeks. This research has created undue confidence in the use of ivermectin as a prophylactic or treatment for COVID-19, has usurped other research agendas, and probably resulted in inappropriate treatment or substandard care of patients.

We recognize that by recommending IPD review by default for meta-analysis of potential therapeutic agents in COVID-19 we are calling for change to nearly universally accepted practice over many decades, but the consequent potential for patient harm on a global scale demands nothing less.